Thromb Haemost 2015; 113(04): 891-902
DOI: 10.1160/TH14-09-0776
Atherosclerosis and Ischaemic Disease
Schattauer GmbH

Protein disulphide-isomerase A2 regulated intracellular tissue factor mobilisation in migrating human vascular smooth muscle cells

Esther Peña
1   Cardiovascular Research Center, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau (UAB), IIB-Sant Pau, Barcelona, Spain
,
Gemma Arderiu
1   Cardiovascular Research Center, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau (UAB), IIB-Sant Pau, Barcelona, Spain
,
Lina Badimon
1   Cardiovascular Research Center, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau (UAB), IIB-Sant Pau, Barcelona, Spain
› Author Affiliations
Further Information

Publication History

Received: 17 September 2014

Accepted after minor revision: 01 January 2014

Publication Date:
24 November 2017 (online)

Summary

Protein-disulphide isomerase family (PDI) are an ER-stress protein that controls TF-procoagulant activity but its role in HVSMC migration and coronary artery disease remains to be elucidated. We aimed to investigate whether in human coronary smooth muscle cells (HVSMC) the ER-stress protein-disulphide isomerase family A member 2 (PDIA2) regulates tissue factor (TF) polarisation during migration and atherosclerotic remodeling. PDIA2 and TF were analysed by confocal microscopy, silenced by small interfering RNAs (siRNA) and their function analysed by transwell and migration assays in vitro and in vivo. PDIA2and TF co-localise in the front edge of motile HVSMC. Silencing PDIA2, as well as silencing TF, reduces migration. PDIA2 silenced cells show increased TF-rich microparticle shedding. In vivo cell-loaded plug implants in nude mice of PDIA2 silenced HVSMC together with microvascular endothelial cells showed a significant impairment in mature microvessel formation. PDIA2 and TF are found in remodelled atherosclerotic plaques but not in healthy coronaries. In conclusion, we demonstrate that TF is chaperoned by PDIA2 to the HVSMC membrane and to the cell migratory front. Absence of PDIA2 impairs TF intracellular trafficking to its membrane docking favoring its uncontrolled release in microparticles. TF-regulated HVSMC migration and microvessel formation is under the control of the ER-protein PDIA2.

 
  • References

  • 1 Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 509-514.
  • 2 Vallot O, Combettes L, Jourdon P. et al. Intracellular Ca (2+) handling in vascular smooth muscle cells is affected by proliferation. Arterioscler Thromb Vasc Biol 2000; 20: 1225-1235.
  • 3 Orr AW, Hastings NE, Blackman BR. et al. Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J Vasc Res 2010; 47: 168-180.
  • 4 Vilahur G, Juan-Babot O, Pena E. et al. Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol 2011; 50: 522-533.
  • 5 Toschi V, Gallo R, Lettino M. et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-599.
  • 6 Peppelenbosch MP, Versteeg HH. Cell biology of tissue factor, an unusual member of the cytokine receptor family. Trends Cardiovasc Med 2001; 11: 335-339.
  • 7 Badimon JJ, Lettino M, Toschi V. et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-1787.
  • 8 Badimon L, Storey RF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2011; 105 (Suppl. 01) S34-S42.
  • 9 Hansen CB, van Deurs B, Petersen LC. et al. Discordant expression of tissue factor and its activity in polarized epithelial cells. Asymmetry in anionic phospholipid availability as a possible explanation. Blood 1999; 94: 1657-1664.
  • 10 Rao LV, Kothari H, Pendurthi UR. Tissue factor: mechanisms of decryption. Front Biosci (Elite Ed) 2012; 04: 1513-1527.
  • 11 Versteeg HH, Ruf W. Thiol pathways in the regulation of tissue factor prothrombotic activity. Curr Opin Hematol 2011; 18: 343-348.
  • 12 Alanen HI, Salo KE, Pekkala M. et al. Defining the domain boundaries of the human protein disulfide isomerases. Antioxid Redox Signal 2003; 05: 367-374.
  • 13 Volkmer J, Guth S, Nastainczyk W. et al. Pancreas specific protein disulfide isomerase, PDIp, is in transient contact with secretory proteins during late stages of translocation. FEBS Lett 1997; 406: 291-295.
  • 14 Fu X, Zhu BT. Human pancreas-specific protein disulfide isomerase homolog (PDIp) is redox-regulated through formation of an inter-subunit disulfide bond. Arch Biochem Biophys 2009; 485: 1-9.
  • 15 Walker AK, Soo KY, Levina V. et al. N-linked glycosylation modulates dimerisation of protein disulfide isomerase family A member 2 (PDIA2). Febs J 2013; 280: 233-243.
  • 16 Langer F, Spath B, Fischer C. et al. Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase. Blood 2013; 121: 2324-2335.
  • 17 Pena E, Arderiu G, Badimon L. Subcellular localisation of tissue factor and human coronary artery smooth muscle cell migration. J Thromb Haemost 2012; 10: 2373-2382.
  • 18 Arderiu G, Pena E, Aledo R. et al. Tissue factor regulates microvessel formation and stabilisation by induction of chemokine (C-C motif) ligand 2 expression. Arterioscler Thromb Vasc Biol 2011; 31: 2607-2615.
  • 19 Pena E, Arderiu G, Badimon L. Tissue Factor Induces Human Coronary Artery Smooth Muscle Cell Motility through Wnt-Signalling. J Thromb Haemost 2013; 11: 1880-1891.
  • 20 Mandal SK, Iakhiaev A, Pendurthi UR. et al. Acute cholesterol depletion impairs functional expression of tissue factor in fibroblasts: modulation of tissue factor activity by membrane cholesterol. Blood 2005; 105: 153-160.
  • 21 Dietzen DJ PK, Tetzloff TA. Lipid rafts are necessary for tonic inhibition of cellular tissue factor procoagulant activity. Blood 2004; 103: 3038-3044.
  • 22 Chen VM, Ahamed J, Versteeg HH. et al. Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry 2006; 45: 12020-12028.
  • 23 Reinhardt C, von Bruhl ML, Manukyan D. et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 2008; 118: 1110-1122.
  • 24 Subirana MT, Juan-Babot JO, Puig T. et al. Specific characteristics of sudden death in a mediterranean Spanish population. Am J Cardiol 2011; 107: 622-627.
  • 25 Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S. et al. Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation 2004; 110: 452-459.
  • 26 Uehara T, Nakamura T, Yao D. et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 2006; 441: 513-517.
  • 27 Tian F, Zhou X, Wikstrom J. et al. Protein disulfide isomerase increases in myocardial endothelial cells in mice exposed to chronic hypoxia: a stimulatory role in angiogenesis. Am J Physiol Heart Circ Physiol 2009; 297: H1078-H1086.
  • 28 Goplen D, Wang J, Enger PO. et al. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res 2006; 66: 9895-9902.
  • 29 Toldo S, Severino A, Abbate A. et al. The role of PDI as a survival factor in cardiomyocyte ischemia. Methods Enzymol 2011; 489: 47-65.
  • 30 Arderiu G, Pena E, Aledo R. et al. Tissue Factor Regulates Microvessel Formation and Stabilisation by Induction of CCL2 Expression. Arterioscler Thromb Vasc Biol 2011; 31: 2607-2615.
  • 31 Arderiu G, Pena E, Aledo R. et al. Tissue factor-Akt signalling triggers microvessel formation. J Thromb Haemost 2012; 10: 1895-1905.
  • 32 Llorente-Cortes V, Martinez-Gonzalez J, Badimon L. LDL receptor-related protein mediates uptake of aggregated LDL in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20: 1572-1579.
  • 33 Llorente-Cortes V, Otero-Vinas M, Hurt-Camejo E. et al. Human coronary smooth muscle cells internalize versican-modified LDL through LDL receptorrelated protein and LDL receptors. Arterioscler Thromb Vasc Biol 2002; 22: 387-393.
  • 34 Otero-Vinas M, Llorente-Cortes V, Pena E. et al. Aggregated low density lipoproteins decrease metalloproteinase-9 expression and activity in human coronary smooth muscle cells. Atherosclerosis 2007; 194: 326-333.
  • 35 Padrό TPE, García-Arguinzonis M, Llorente-Cortes V, Badimon L. Low-density lipoproteins impair migration of human coronary vascular smooth muscle cells and induce changes in the proteomic profile of myosin light chain. Cardiovasc Res 2008; 97: 650-657.
  • 36 Comeau JW, Costantino S, Wiseman PW. A guide to accurate fluorescence microscopy colocalisation measurements. Biophys J 2006; 91: 4611-4622.
  • 37 Arderiu GCI, Carrio M, East L, Boudreau N. HoxA5 promotes vascular stability via increases in Akt and retention of β-catenin in adherents junctions. CAM 2007; 01: 185-195.
  • 38 Pena E, Padro T, Molins B. et al. Proteomic signature of thrombin-activated platelets after in vivo nitric oxide-donor treatment: coordinated inhibition of signalling (phosphatidylinositol 3-kinase-gamma, 14–3-3zeta, and growth factor receptor-bound protein 2) and cytoskeleton protein translocation. Arterioscler Thromb Vasc Biol 2011; 31: 2560-2569.
  • 39 Penn MS, Patel CV, Cui MZ. et al. LDL increases inactive tissue factor on vascular smooth muscle cell surfaces: hydrogen peroxide activates latent cell surface tissue factor. Circulation 1999; 99: 1753-1759.
  • 40 Camino-Lopez S, Llorente-Cortes V, Sendra J. et al. Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells. Cardiovasc Res 2007; 73: 208-216.
  • 41 Suades R, Padro T, Alonso R. et al. Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in familial hypercholesterolaemia patients. Thromb Haemost 2014; 111: 111-121.
  • 42 Suades R, Padro T, Alonso R. et al. Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells. Thromb Haemost 2013; 110: 366-377.